What “good” looks like
A diagnostic testing clinic should start with a decision, not a shopping cart. A licensed clinician can state why each test is being ordered, whether it is screening or diagnosis, and what result would change care this year. CDC materials on clinical laboratories and FDA pages on in vitro diagnostics treat assays as medical devices and lab processes, not as personality scores. A good clinic uses indicated tests and explains uncertainty.
Laboratory quality is visible. For U.S. human clinical testing, ask for the performing laboratory and its CLIA certificate. CDC clinical-laboratory pages describe CLIA as quality oversight. CLIA does not, by itself, prove that a boutique marker has clinical validity or that a “optimal” range predicts longer life. It does tell you the site is in the clinical-lab system rather than a research-only black box.
Genetics need a higher bar. CDC genetic-testing and counseling pages treat medical DNA tests as care decisions that can affect relatives, surveillance, and insurance conversations. A good clinic offers pretest counseling, consent, a plan for variants of uncertain significance, and confirmatory testing when needed. A fear-based ancestry-style panel sold as a longevity upgrade is not that service.
Follow-up is part of the product. Someone licensed must review every result, call critical values, confirm surprises, and own incidental findings. A portal dump with a color dashboard and a supplement link is not diagnostic care. Keep USPSTF-aligned screening—blood pressure, cervical, breast, colorectal, lung when indicated—on the calendar even if a cash panel looks “complete.”
Credentials and scope to verify
Look up the person who interprets results and decides next steps. That should be a physician, nurse practitioner, or physician assistant, with a genetic counselor or medical geneticist for germline tests that change family risk. A health coach or salesperson should not deliver a cancer-gene result. Imaging needs a radiologist. Maximal exercise testing needs emergency equipment and trained staff.
Ask who the laboratory director is and where the specimen goes. FDA in-vitro-diagnostic pages distinguish authorized assays from tests used outside their intended use. Direct-to-consumer reports may still need confirmatory clinical testing. If the clinic cannot name the manufacturer, method, and intended-use population, you cannot judge the claim.
Scope includes privacy. Genetic and biometric data are identifying. Ask about research sharing, retention, deletion, and who else can see the file. A consumer platform is not automatically a treating clinician’s record. If you would not want that dataset sold, get the policy in writing before you spit in a tube.
Emergency and incidental-finding scope matters for imaging and stress tests. Contrast reactions, arrhythmia during exercise, and a nodule on a whole-body scan need a named owner. A clinic that sells the scan but will not manage the finding is transferring risk to you and your primary-care clinician without asking.
Questions to ask
Bring the list. Require specific answers.
- Which result would change a medicine, referral, or screening plan this year?
- What laboratory performs the test, and what is its CLIA status?
- For genetics: who counsels me, what is the variant-of-uncertain-significance policy, and how is family risk handled?
- Is this a clinical assay, a research-use test, or a direct-to-consumer report that needs confirmation?
- Who calls critical values, and who owns incidental imaging or lab findings?
- What is the itemized price including interpretation, repeats, counseling, and follow-up procedures?
Ask how the panel compares with USPSTF recommendation topics for your age and risk. If the clinic cannot map its menu onto those questions, it is selling volume. Ask whether “optimal” ranges come from outcome trials or from marketing. FDA consumer pages warn that a consumer test is not a diagnosis.
For biological-age clocks and huge biomarker stacks, ask for the model name, published performance, and a stop rule. One optional research score is enough. Repeat cash testing that only feeds supplements is not monitoring.
Red flags
Fear is the main sales tool to reject. Language about silent killers, hidden toxins, or a last chance to catch everything is designed to override judgment. USPSTF screening is organized by evidence of benefit and harm, including false positives. A clinic that mocks guideline screening while selling an unvalidated mega-panel has inverted that logic.
Walk away from guaranteed early detection, age reversal, or longevity improvement. Walk away from “FDA registered” offered as proof of effectiveness. Registration is not authorization for every wellness claim. Walk away if every abnormality becomes an in-house IV, hormone, or supplement—the clinic is generating its own demand.
Genetics without counseling, consent, or a confirmatory path is a red flag. So is using a consumer kit to skip indicated hereditary testing, or telling you a negative wellness screen means your family cancer history no longer matters. CDC notes that no single genetic test finds every condition.
Whole-body CT marketed to healthy people without a radiation discussion, and multi-cancer blood tests sold as a replacement for cancer-specific screening, are also walk-away signs. A pretty report does not cancel a missed mammogram or colonoscopy.
Cost, time, and logistics
Price interpretation and downstream care, not only collection. Itemize consultation, draw or scan, laboratory or imaging fees, genetic counseling, repeat confirmatory tests, and the biopsy or specialist visit an incidental finding can trigger. Insurance may cover indicated, USPSTF-aligned tests and some diagnostic work. Cash executive panels often exclude the expensive follow-up they create.
Time includes fasting, medication holds, and a visit to review results—not only the day you give blood. Genetics can take weeks and may require a second appointment. If the clinic mails a 40-page PDF with no call, you paid for data entry.
Logistics include sending records to your primary-care clinician, keeping a medication list, and deciding in advance which optional markers you will ignore. Set a rule: keep tests that change a decision; drop fear-based add-ons. If you have a symptom—a lump, chest pain, unexplained bleeding—use ordinary evaluation first. A wellness panel is not an emergency department.
Choose the clinic that uses a CLIA laboratory, orders indicated tests, and counsels genetics like medical information. Decline the one that sells fear by the biomarker. Testing is useful when it changes care. It is noise when it only changes your heart rate in the waiting room.
Frequently Asked Questions
References
CDC: Clinical Laboratory Systems
https://www.cdc.gov/clinical-laboratory-systems/php/about/index.htmlFDA: In Vitro Diagnostics
https://www.fda.gov/medical-devices/in-vitro-diagnosticsFDA: Direct-to-Consumer Tests
https://www.fda.gov/medical-devices/in-vitro-diagnostics/direct-consumer-testsCDC: Genetic Counseling
https://www.cdc.gov/genomics-and-health/counseling-testing/genetic-counseling.htmlCDC: Genetic Testing
https://www.cdc.gov/genomics-and-health/counseling-testing/genetic-testing.htmlUSPSTF: Recommendation Topics
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics
Your Privacy Choices